alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › exenatide

exenatide

4 studies tagged exenatide, dated 2017-11-20 to 2019-05-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity 2019-05-01
  2. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease 2019-01-01
  3. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury 2018-11-22

Studies

4 studies carry this tag.

Date range

2017 to 2019

Top journals

  • Fundamental & clinical pharmacology 1
  • Journal of Alzheimer's disease : JAD 1
  • Neurobiology of disease 1
  • The International journal of neuroscience 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The International journal of neuroscience 2019-05-01 Drug development

    Diabetes mellitus (DM) is one of the most common metabolic disorders characterized by hyperglycemia due to insufficiency of insulin and/or insulin resistance.

  2. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease : JAD 2019-01-01 Drug development

    Alzheimer's disease (AD) is a multifactorial condition in which, along with amyloid-β (Aβ) and tau-related pathology, the synergistic activity of co-morbidity factors promote the onset and progression of the disease.

  3. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of disease 2018-11-22 Drug development

    Traumatic brain injury (TBI) is a neurodegenerative disorder for which no effective pharmacological treatment is available.

  4. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Fundamental & clinical pharmacology 2017-11-20 Drug development

    Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has modulating effects on insulin release.

All topic tags with their study counts